Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Galapagos N.V. is active in the Biotechnology & Pharmaceuticals technology area, where it currently faces 3 pending office actions. This volume of activity is distributed across 3 distinct examiners, indicating that each pending matter is being reviewed by a different individual. Such a distribution suggests a variety of technical sub-specialties within the company's biotech filings.
The portfolio's reach extends into 3 distinct art units, matching the number of distinct examiners. This relationship between examiners and art units reflects a spread across the patent office's organizational structure. Prosecution teams must prepare for different sets of examiner behaviors and art unit norms simultaneously within the Biotechnology & Pharmaceuticals field.
ENGLISH, CONNOR KENNEDY is the busiest examiner, though this individual is responsible for only 1 busiest examiner pending action. With the total 3 pending office actions split among different people, no single examiner dominates the portfolio's current trajectory. This lack of concentration means that the overall prosecution risk is diversified across multiple decision-makers.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038667 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF FIBROTIC DISEASES | PIHONAK, SARAH | 150d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038667 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF FIBROTIC DISEASES | PIHONAK, SARAH | 150d overdue |
| 18863014 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | ENGLISH, CONNOR KENNEDY | — |
| 18578604 | TREATMENT OF INFLAMMATORY DISEASES | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1624 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863014 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18578604 | TREATMENT OF INFLAMMATORY DISEASES | MARTIN, KEVIN STEPHEN | 1624 | §103§112DP | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18038667 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF FIBROTIC DISEASES | PIHONAK, SARAH | 1627 | §101§102§112 | Non-Final OA | 150d overdue | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGalapagos N.V. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Connor Kennedy English has the most, with 1 of Galapagos N.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
